Health Canada – C. difficile Further Concerns – Promising Solutions Regulatory Failure – Policy Action

Health Canada – C. difficile Further Concerns – Promising Solutions Regulatory Failure – Policy ActionOTTAWA, On:  Further to information released on April 9 and April 30, today’s focus is on further concerns and promising solutions.  The Drug Safety & Effectiveness Network (DSEN) report of 2012 confirms concerns about the strong association between common stomach medications and C. difficile infections (CDI). “If the regulator cannot or will not act in the public interest then it falls to policy makers to advance the public interest and adjust the mandate of the regulator.” Today, I wish to draw attention to research that further links these medications with increased risk ....[click here for full story]

Hospital Infections, Drugs, Deaths What is Wrong with Health Canada?

OTTAWA, On: In 2005, I was assured by the Health Minister of the day that Health Canada was actively investigating C. difficile deaths in Canadian hospitals and the relation to stomach acid suppressant drugs called Proton Pump Inhibitors (PPIs).   A study by the Canadian Nosocomial Infection Surveillance Program (CNISP) would get to the bottom of it.  It didn’t.  The study presented in 2007 failed to collect data on the PPI issue. (Amazingly it purports to be the most extensive review on the subject in North America and useful as a ....[click here for full story]

M501 - National Strategy for Innovation, Effectiveness and Cost-effectiveness in Sustainable Health Care

M501 - National Strategy for Innovation, Effectiveness and Cost-effectiveness in Sustainable Health Care On April 7th, 2014 Dr James Lunney Member of Parliament for Nanaimo-Alberni tabled Motion M501. It reads: That, in the opinion of the House, the government, in concert with provincial and territorial partners, should develop a National Strategy for Innovation, Effectiveness and Cost-effectiveness in Sustainable Health Care that: 1) Establishes regional centers for collaborative research and experimentation with innovative models that:(a) focus on effectiveness and cost-effectiveness, (b) are collaborative and interdisciplinary in character, (c) team up integrative medicine with allied professions, (d) utilize optimized information technology to document outcomes, (e) foster competition for better health care ....[click here for full story]


  • 501

  • Vitamin D